Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Clinical trial NCT05267262 · COMPLETED

Trial details

NCT number: NCT05267262
Sponsor: River 3 Renal Corp.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Alport Syndrome Focal Segmental Glomerulosclerosis

Start date: 2022-06-15
Primary completion: 2025-05-21
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.